- Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
- Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
- Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
On Wednesday, Century Therapeutics Inc (IPSC:NSQ) closed at 2.27, 77.34% above the 52 week low of 1.28 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.22 |
---|---|
High | 2.32 |
Low | 2.18 |
Bid | 2.21 |
Offer | 2.32 |
Previous close | 2.21 |
Average volume | 683.00k |
---|---|
Shares outstanding | 84.50m |
Free float | 60.62m |
P/E (TTM) | -- |
Market cap | 186.75m USD |
EPS (TTM) | -2.22 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼